Presentation (CTI)

OBJECTIVES: To estimate and compare asthma incidence, demographic patterns, and treatment profiles using two large-scale real-world databases in Spain: Telotrón® and The Andalusian Population Health Database (BPS).
METHODS: We conducted a retrospective observational study (2018-2024) using Telotrón®, a large-scale clinical database covering over 2.2 million individuals across seven Autonomous Communities in Spain. Telotrón® includes both primary care and hospital records and offers a country-representative view. For comparative purposes, BPS, which includes data from a single region, was also analyzed. New asthma diagnoses were identified using ICD-10 code J45 and ICD-9 493. We calculated incidence by sex and age group and compared prescribing trends between 2021 and 2023 by therapeutic class.
RESULTS: Asthma incidence ranged from 4.0 to 6.2 per 1,000 population in Telotrón® and 3.4 to 5.1 in BPS, with higher rates in women. A bimodal age distribution was observed in both datasets: in Telotrón®, 23.5% of cases were in those aged 0-15 and 24.5% in those aged 30-45; in BPS, 33.2% and 19.4%, respectively. ICS/LABA was the most prescribed class and remained stable over time, accounting for 39.89% of prescriptions in Telotrón® and 32.91% in BPS. Telotrón® also showed a higher proportion of SABA and biologic treatments. Among biologics, omalizumab was the most prescribed in both databases, accounting for 53.06% in Telotrón® and 45.66% in BPS. Dupilumab and Mepolizumab showed different percentages.
CONCLUSIONS: Findings from Telotrón® and BPS were consistent in terms of asthma incidence, demographics, and treatment, supporting their use as complementary sources of real-world evidence. Telotrón® stands out for its broad geographic coverage, monthly data updates, and current treatments records. These enable faster study set-up and ongoing monitoring. These features make it especially suited for research on asthma and other conditions with seasonal or geographic variation